scholarly journals Long-term survival in renal transplant recipients with graft function

2000 ◽  
Vol 57 (1) ◽  
pp. 307-313 ◽  
Author(s):  
Akinlolu O. Ojo ◽  
Julie A. Hanson ◽  
Robert A. Wolfe ◽  
Alan B. Leichtman ◽  
Lawrence Y. Agodoa ◽  
...  
Drugs ◽  
2004 ◽  
Vol 64 (18) ◽  
pp. 2047-2073 ◽  
Author(s):  
Johannes M M Boots ◽  
Maarten H L Christiaans ◽  
Johannes P van Hooff

2017 ◽  
Vol 18 (4) ◽  
pp. 381-392 ◽  
Author(s):  
Qinxia Xu ◽  
Xiaoyan Qiu ◽  
Zheng Jiao ◽  
Ming Zhang ◽  
Jianping Chen ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Vatsa Dave ◽  
Kevan R. Polkinghorne ◽  
Khai Gene Leong ◽  
John Kanellis ◽  
William R. Mulley

Abstract The evidence supporting an initial mycophenolate mofetil (MMF) dose of 2 g daily in tacrolimus-treated renal transplant recipients is limited. In a non-contemporaneous single-centre cohort study we compared the incidence of leukopaenia, rejection and graft dysfunction in patients initiated on MMF 1.5 g and 2 g daily. Baseline characteristics and tacrolimus trough levels were similar by MMF group. MMF doses became equivalent between groups by 12-months post-transplant, driven by dose reductions in the 2 g group. Leukopaenia occurred in 42.4% of patients by 12-months post-transplant. MMF 2 g was associated with a 1.80-fold increased risk of leukopaenia compared to 1.5 g. Rejection occurred in 44.8% of patients by 12-months post-transplantation. MMF 2 g was associated with half the risk of rejection relative to MMF 1.5 g. Over the first 7-years post-transplantation there was no difference in renal function between groups. Additionally, the development of leukopaenia or rejection did not result in reduced renal function at 7-years post-transplant. Leukopaenia was not associated with an increased incidence of serious infections or rejection. This study demonstrates the initial MMF dose has implications for the incidence of leukopaenia and rejection. Since neither dose produced superior long-term graft function, clinical equipoise remains regarding the optimal initial mycophenolate dose in tacrolimus-treated renal transplant recipients.


2021 ◽  
Vol 19 (1) ◽  
pp. 42-49
Author(s):  
Anil Kumar Das ◽  
Ramesh Sharma ◽  
Ashish Karn

Background: The availability of potent immunosuppressants has paved the path towards decreased incidence of graft rejection and long term survival of the renal transplant recipients. But, with the increased life span of the patients and long term use of immunosuppressants, there has been an increase in various skin conditions; ranging from various infections to some life-threatening cutaneous malignancies. Objectives: This study was carried out to determine the pattern of different cutaneous manifestations in renal transplant recipients at Tribhuvan University Teaching Hospital, to identify the infectious and non-infectious skin manifestations in these patients and their relation with the duration of transplantation. Methodology: The present study was a hospital based cross-sectional descriptive study conducted at Tribhuvan University Teaching Hospital, Kathmandu; Department of Internal Medicine, Transplant Outpatient department and Outpatient department of Department of Dermatology from June 2013 to May 2014. A total of 114 renal transplant recipients were enrolled in the study. Results: A total of 114 renal transplant recipients with a mean age of 37.56±11.10 years were studied. The immunosuppressive regimen consisted of combinations including tacrolimus, prednisolone,   mycophenolate mofetil/azathioprine along with supportive medications like antivirals, antibiotics and antihypertensives. Out of all those studied, 60 patients had a total of 61 cutaneous manifestations. The mean duration from date of transplantation to presentation to the transplant OPD for infectious dermatoses was 688.4 days (1.88 years) and for iatrogenic dermatoses was 67.5 days. The most common cutaneous manifestation was acne (41%) followed by fungal infections (27.9%) consisting of pityriasis versicolor (n=9), dermatophytosis (n=6) and candidiasis (n=2); viral infections (18%) consisting of verruca (n=4), herpes zoster (n=4) and herpes simplex (n=3); bacterial infections (4.9%) consisting of folliculitis (n=2) and erythema chronicum migrans (n=1). Gingival hyperplasia was observed in a single patient. Other cutaneous manifestations like seborrheic dermatitis and xerosis were also observed in 2 patients each during the study.   Conclusion: Renal transplant recipients are susceptible to acquire various cutaneous manifestations as a result of long term immunosuppression and also due to adverse effects of the drugs used. This knowledge helps the transplant physicians for regular dermatologic screening of these patients for early diagnosis and treatment of the skin lesions.


Sign in / Sign up

Export Citation Format

Share Document